Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Astaxanthin on Hormonal Parameters and Oxidative Stress Indices in Patients With Polycystic Ovary Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03991286
Recruitment Status : Completed
First Posted : June 19, 2019
Last Update Posted : April 13, 2021
Sponsor:
Information provided by (Responsible Party):
Tehran University of Medical Sciences

Brief Summary:

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting women of reproductive age It is hypothesized that ∼20 fold increase in reactive oxygen species (ROS) generation in Follicular fluid (FF) and granulosa cells of PCOS women plays an adverse role in affecting the IVF success rate. Astaxanthin (3,3'-dihydroxy-β,β'-carotene-4,4'-dione) is a nonprovitamin A carotenoid classified as a xanthophyll and is found in high amounts in the red pigment of crustacean shells (e.g., crabs, shrimp), salmon, trout, and asteroides. It has been demonstrated that astaxanthin displays a wide variety of biological activities, including anti-oxidative, anticancer, and anti-inflammatory effects.

investigators aim to investigate the effect on Astaxanthin administrating on reducing of ROS in FF and induction of antioxidant response elements in PCOS women.


Condition or disease Intervention/treatment Phase
PCOS Dietary Supplement: Astaxanthin 8 mg Other: placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: The Effect of Astaxanthin on Hormonal Parameters and Oxidative Stress Indices in Serum, and Induction of Signaling Pathways in Granulosa Cells in Patients With Polycystic Ovary Syndrome
Actual Study Start Date : January 20, 2020
Actual Primary Completion Date : November 1, 2020
Actual Study Completion Date : April 7, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Astaxanthin

Arm Intervention/treatment
Placebo Comparator: Placebo

Drug: Placebo

Ovulatory Agent:

Clomiphene Citrate

Other: placebo
Matching placebo pill

Experimental: experimental

Drug: Astaxanthin 8mg

Drug: Ovulatory Agent Clomiphene Citrate

Dietary Supplement: Astaxanthin 8 mg
experimental
Other Name: Algalife, Icelandic Astaxanthin




Primary Outcome Measures :
  1. Serum glucose milligrams per deciliter (mg/dL) levels [ Time Frame: 8 months ]
    This parameter will measure using Enzyme-Linked. Immunosorbent Assays (ELISAs)

  2. Serum insulin milli-International unit/milliliter (mIU/ml) [ Time Frame: 8 months ]
    This parameter will measure using Enzyme-Linked. Immunosorbent Assays (ELISAs)

  3. Serum Follicle stimulating hormone (FSH) mIU/ml levels [ Time Frame: 8 months ]
    This parameter will measure using Enzyme-Linked. Immunosorbent Assays (ELISAs)

  4. Serum testosterone testosterone [ Time Frame: 8 months ]
    This parameter will measure using Enzyme-Linked. Immunosorbent Assays (ELISAs)

  5. Serum hormone (LH) mIU/ml, [ Time Frame: 8 months ]
    This parameter will measure using Enzyme-Linked. Immunosorbent Assays (ELISAs)


Secondary Outcome Measures :
  1. Number of oocytes retrieved [ Time Frame: Day1(from the day of oocyte retrieval to fertilization confirmation) ]
    using polarized light microscopy

  2. Number of mature(MII) oocyte [ Time Frame: Day1(from the day of oocyte retrieval to fertilization confirmation) ]
    using polarized light microscopy



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Diagnosed PCOS cases according to the National Institute of Health criteria (NIH consensus criteria) and Rotterdam criteria

Exclusion Criteria:

  • Menopause, pregnant or lactating females
  • individuals with diabetes
  • those with hepatic,renal, thyroid or cardiovascular disorders
  • patients with elevated levels of prolactin
  • those who were taking antioxidant supplements within the last 3 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03991286


Locations
Layout table for location information
Iran, Islamic Republic of
Shariati Hospital
Tehran, Iran, Islamic Republic of
Sponsors and Collaborators
Tehran University of Medical Sciences
Investigators
Layout table for investigator information
Study Chair: Fardin Amidi, professor Tehran University of Medical Sciences
Layout table for additonal information
Responsible Party: Tehran University of Medical Sciences
ClinicalTrials.gov Identifier: NCT03991286    
Other Study ID Numbers: 98-01-30-41687
First Posted: June 19, 2019    Key Record Dates
Last Update Posted: April 13, 2021
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Tehran University of Medical Sciences:
PCOS
Astaxanthin
ROS
Additional relevant MeSH terms:
Layout table for MeSH terms
Polycystic Ovary Syndrome
Ovarian Cysts
Cysts
Neoplasms
Ovarian Diseases
Adnexal Diseases
Gonadal Disorders
Endocrine System Diseases